Critical Care Clinical Pharmacy Specialist University of Texas MD Anderson Center Houston, Texas
Disclosure(s): No relevant financial relationship(s) to disclose.
Disclosure(s):
Anne Rain Brown, PharmD, BCCCP, FCCM: No relevant financial relationship(s) to disclose.
IEC or adoptive cell therapy utilize immune cells from a donor (allogenic) or patient (autologous) to target tumor cells. One type of ACT are cells genetically engineered to express chimeric antigens (CARs). Although ACTs can overcome the tumor’s ability to evade the immune system, the launch of a powerful immune response produce significant toxicities. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are the most common toxicities associated with CAR-T therapy, requiring admission and management in the ICU. In this topic, we will provide an update of the recently approved FDA products and their toxicity profiles.
Presentations in this session: Update on FDA CAR-T Products and Toxicity Management Guidelines - Anne Rain Brown Emerging Cellular Therapies and Associated Toxicity: What's Different From CAR-T Therapy - Colleen McEvoy Recognition and Management of HLH in the Context of Cellular Therapy - Matthew Hensley Update on Cost and ICU Resource Utilization for Administration of Cellular Therapy: A Review of Current Data - Cristina Gutierrez
